1. Smith, Eric L, Harrington, Kim, Staehr, Mette, Sather, Blythe, Brentjens, Renier J. . GPRC5D is a target for the immunotherapy of multiple myeloma with rationally designed CAR T cells. In Science translational medicine, 11, . doi:10.1126/scitranslmed.aau7746. https://pubmed.ncbi.nlm.nih.gov/30918115/
2. Zhou, Dian, Sun, Qian, Xia, Jieyun, Xu, Kailin, Li, Zhenyu. 2024. Anti-BCMA/GPRC5D bispecific CAR T cells in patients with relapsed or refractory multiple myeloma: a single-arm, single-centre, phase 1 trial. In The Lancet. Haematology, 11, e751-e760. doi:10.1016/S2352-3026(24)00176-5. https://pubmed.ncbi.nlm.nih.gov/39059405/
3. Derrien, Jennifer, Gastineau, Sarah, Frigout, Antoine, Touzeau, Cyrille, Letouzé, Eric. 2023. Acquired resistance to a GPRC5D-directed T-cell engager in multiple myeloma is mediated by genetic or epigenetic target inactivation. In Nature cancer, 4, 1536-1543. doi:10.1038/s43018-023-00625-9. https://pubmed.ncbi.nlm.nih.gov/37653140/
4. John, Mara, Helal, Moutaz, Duell, Johannes, Riedel, Angela, Rasche, Leo. . Spatial transcriptomics reveals profound subclonal heterogeneity and T-cell dysfunction in extramedullary myeloma. In Blood, 144, 2121-2135. doi:10.1182/blood.2024024590. https://pubmed.ncbi.nlm.nih.gov/39172759/
5. Yu, Miao, He, Xiuting, Liu, Ting, Li, Jie. 2023. lncRNA GPRC5D-AS1 as a ceRNA inhibits skeletal muscle aging by regulating miR-520d-5p. In Aging, 15, 13980-13997. doi:10.18632/aging.205279. https://pubmed.ncbi.nlm.nih.gov/38100482/
6. Cohen, Yossi, Gutwein, Odit, Garach-Jehoshua, Osnat, Bar-Haim, Adina, Kornberg, Abraham. 2013. GPRC5D is a promising marker for monitoring the tumor load and to target multiple myeloma cells. In Hematology (Amsterdam, Netherlands), 18, 348-51. doi:10.1179/1607845413Y.0000000079. https://pubmed.ncbi.nlm.nih.gov/23510526/
智鼠故事 
